DDInter702 DDInter1676
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Etoposide {u} (Compound) resembles {v} (Compound) Podofilox
Etoposide {u} (Compound) treats {v} (Disease) urinary bladder cancer
Etoposide {u} (Compound) binds {v} (Gene) GSTT1
Etoposide {u} (Compound) upregulates {v} (Gene) COL11A1
Etoposide {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Etoposide {u} (Compound) downregulates {v} (Gene) AURKB
Etoposide {u} (Compound) causes {v} (Side Effect) Necrolysis epidermal
Etoposide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Etoposide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Trovafloxacin
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alefacept
Etoposide (Compound) resembles Podofilox (Compound)
Etoposide (Compound) treats urinary bladder cancer (Disease)
Etoposide (Compound) binds GSTT1 (Gene)
Etoposide (Compound) upregulates COL11A1 (Gene)
Etoposide (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Etoposide (Compound) downregulates AURKB (Gene)
Etoposide (Compound) causes Necrolysis epidermal (Side Effect)
Etoposide may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Etoposide may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Alefacept